Journal
TOXINS
Volume 11, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/toxins11050303
Keywords
snake venom; Tirofiban; Eptifibatide; Vipegitide; anti-platelet drug; acute coronary syndrome; percutaneous coronary intervention; clinical trial; adverse effect
Categories
Funding
- German-Israeli Foundation [GIF-994-3.9/2008]
- National Cancer Institute [1R01CA133262-01A2, 1R01CA100145-01A1]
Ask authors/readers for more resources
Snake venoms are attractive natural sources for drug discovery and development, with a number of substances either in clinical use or in research and development. These drugs were developed based on RGD-containing snake venom disintegrins, which efficiently antagonize fibrinogen activation of IIb3 integrin (glycoprotein GP IIb/IIIa). Typical examples of anti-platelet drugs found in clinics are Integrilin (Eptifibatide), a heptapeptide derived from Barbourin, a protein found in the venom of the American Southeastern pygmy rattlesnake and Aggrastat (Tirofiban), a small molecule based on the structure of Echistatin, and a protein found in the venom of the saw-scaled viper. Using a similar drug discovery approach, linear and cyclic peptides containing the sequence K(R)TS derived from VP12, a C-type lectin protein found in the venom of Israeli viper venom, were used as a template to synthesize Vipegitide, a novel peptidomimetic antagonist of 21 integrin, with anti-platelet activity. This review focus on drug discovery of these anti-platelet agents, their indications for clinical use in acute coronary syndromes and percutaneous coronary intervention based on several clinical trials, as well as their adverse effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available